| Action Summary | Adds Pompe disease and mucopolysaccharidosis type 1 (MPS 1) to the Virginia Newborn Screening System's core panel of heritable disorders and genetic diseases |
| Chapters Affected | Only affects this chapter. |
| Executive Branch Review | This Action is exempt from Article 2 of the Administrative Process Act. The normal executive branch review process is not required. As such, it can be submitted directly for publication and is effective upon publication. Exempt Citation: Section 2.2-4006 A 4 a of the Code of Virginia |
| RIS Project | Yes [005461] |
|
Is Federal action a driving factor in this regulatory change? If so, please provide a specific reference to the law, regulation
or court case.
No
|
|
| Associated Mandates | Amend Newborn Screening Regulations |
| New Periodic Review | This action will not be used to conduct a new periodic review. |
| Stage ID | Stage Type | Status |
|---|---|---|
| 8367 | Final | Stage complete. This regulation became effective on 01/01/2019. |
| Name / Title: | Michael Capps / Sr. Policy Analyst |
| Address: |
James Madison Building 109 Governor Street Richmond, VA 23219 |
| Email Address: | boardofhealth@vdh.virginia.gov |
| Phone: | (804) 864-7190 FAX: (804)864-7022 TDD: ()- |